Kymera Therapeutics Q2 FY26 earnings call KYMR

Jared Gollob, Chief Medical Officer, is retiring after 8 years, transitioning to an advisory role through year-end. Terence Rooney has been appointed as the new Chief Medical Officer, bringing extensive experience in immunology development and commercialization from J&J and Eli Lilly. This transition is part of Kymera's broader strategy to build capabilities for a growing late-stage clinical portfolio and commercialization, aiming to redefine treatment paradigms with oral medicines.

Enrollment for the Phase 2b AD trial of KT-621 was completed approximately six months ahead of schedule, driven by compelling preclinical and Phase 1b data, strong investigator enthusiasm for an oral therapy, and efficient clinical execution. Top-line data are now expected by year-end 2026, with Phase III initiation planned for mid-2027, both accelerated by six months. The company emphasizes the significant unmet need for an effective, safe oral therapy in AD, targeting the estimated 43 million adults in major markets not well-served by existing treatments.

Enrollment is ongoing for the BREADTH Phase 2b trial in asthma, with top-line data anticipated in late 2027. Management highlights strong KOL enthusiasm for an effective oral therapy in type 2 asthma, which could address a significant unmet need for moderate to severe patients. An open-label extension study has been initiated for asthma patients to gather long-term data. KT-621 is positioned to potentially become the first oral therapy for individual type 2 inflammatory diseases and address the full spectrum of type 2 diseases and associated comorbidities.

The oral IRF5 degrader, KT-579, is on track to report Phase I healthy volunteer data in Q4 2026. IRF5 is identified as a genetically validated driver of innate immunity dysfunction and inflammation across multiple autoimmune diseases like lupus. The Phase I study aims to demonstrate robust and safe IRF5 degradation (over 90%) and modulate key inflammatory pathway biomarkers. Following these results, KT-579 is planned to advance into a proof-of-concept study in lupus patients, addressing a critical need for more efficacious and well-tolerated oral therapies.

Kymera's partnered programs are also advancing, with KT-485 (IRAK4 degrader with Sanofi) entering Phase I development, triggering a $20 million milestone payment. KT-200 (CDK2 molecular glue with Gilead) is progressing towards an IND and clinical start next year. The company aims to bring at least one new molecule into clinical development annually, with a strong focus on immunology indications with validated targets and unmet oral treatment needs.

The company ended Q2 FY26 with approximately $1.5 billion in cash, cash equivalents, and investments, providing a runway into 2029. This financial position is expected to fund the completion of KT-621 Phase 2b trials in AD and asthma, the full progression of KT-579 through its planned lupus PoC study, and the beginning stages of KT-621 Phase III studies in both AD and asthma. Kymera emphasizes a disciplined approach to capital allocation while investing in research and building commercial capabilities.